ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases
ISOS aims to create a personalized bioreactor using engineered probiotics for on-demand delivery of therapeutic compounds to treat chronic diseases like age-related macular degeneration.
Projectdetails
Introduction
In ISOS, we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing complex ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor. ISOS is designed to treat chronic diseases requiring lengthy treatments.
Mechanism of Action
The encapsulated GEB populations produce the therapeutic molecules "on demand," stimulated by the signals of the pathological environment within the patient, i.e., inflammation and/or reactive oxygen species. Bacteria populations interact among themselves to maintain a dynamic equilibrium of the GEB species and to guarantee the survival of the drug-producing GEB as long as the disease persists.
Biosafety and Regulatory Compliance
The GEB ecosystem is designed in such a way that bacteria cannot survive outside of the encapsulating biomaterial, to meet future biosafety and regulatory requirements. The design and configuration of the GEB ecosystem will be personalized for each patient, and it will be done using in-silico tools and synthetic biology.
Proof-of-Concept
As a Proof-of-Concept, we propose to engineer an implantable GEB-based bioreactor for the therapy of the wet form of age-related macular degeneration (wAMD), which is caused by an abnormal production of Vascular Endothelial Growth Factor (VEGF). This Proof-of-Concept will demonstrate the ability of ISOS to replace the repeated intraocular injections of Anti-VEGF molecules (current treatment) with a single ISOS bioreactor that will enhance the therapeutic response and minimize side effects due to the molecular crosstalk between ISOS and the pathological environment.
Future Perspectives
ISOS will establish the principles of a new generation of therapeutic products that will use recombinant probiotic bacteria strains libraries for personalized treatments with rigorous control of local drug production and efficient delivery based on dynamic variation of pathological signals.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.433.300 |
Totale projectbegroting | € 2.433.300 |
Tijdlijn
Startdatum | 1-12-2023 |
Einddatum | 30-11-2026 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- SILK BIOMED, S.L.penvoerder
- UNIVERSIDAD COMPLUTENSE DE MADRID
- UNIVERSITAET LEIPZIG
- FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
- ALIEN TT ITALY S.R.L.
- INDEEP ARTIFICIAL INTELLIGENCE SL
- UNIVERSITY OF NORTHUMBRIA AT NEWCASTLE
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTHiNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment. | EIC Pathfinder | € 3.194.343 | 2025 | Details |
Bacteria Biofilm as bio-factory for tissue regenerationBIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes. | EIC Pathfinder | € 2.903.862 | 2023 | Details |
On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic DrugsDevelop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery. | EIC Pathfinder | € 2.606.250 | 2022 | Details |
PRInted Symbiotic Materials as a dynamic platform for Living Tissues productionPRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications. | EIC Pathfinder | € 2.805.403 | 2022 | Details |
Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of ChemotherapeuticsThe project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer. | EIC Pathfinder | € 4.420.511 | 2023 | Details |
INTELLIGENT ENCAPSULATION AND SCREENING PLATFORM FOR PRECISION DELIVERY OF PROBIOTICS TO IMPROVE GUT HEALTH
iNSIGHT aims to develop precision probiotics through innovative microencapsulation for targeted delivery, enhancing gut health and addressing related diseases using advanced technology and personalized treatment.
Bacteria Biofilm as bio-factory for tissue regeneration
BIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes.
On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs
Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.
PRInted Symbiotic Materials as a dynamic platform for Living Tissues production
PRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications.
Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics
The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Microbial Synthetic in vivo Cell Therapy SystemsThe MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways. | ERC Starting... | € 1.499.938 | 2023 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC Proof of... | € 150.000 | 2023 | Details |
Redesigning aortic endograft: enabling in-situ personalized aneurysm healingEPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models. | ERC Consolid... | € 1.991.225 | 2024 | Details |
Engineering of bacteria to see lightEOS aims to develop biohybrid living materials by inducing light sensitivity in motile bacteria for remote drug delivery, using a novel "optobacterial-stimulation" method. | ERC Starting... | € 1.500.000 | 2024 | Details |
Intelligent Device and Computational Software to Control Mechanical Stress and Deformation for Biological TestingISBIOMECH aims to develop a novel intelligent system for controlling mechanical environments in biological testing, enhancing in-vitro therapies and drug discovery for various pathologies. | ERC Proof of... | € 150.000 | 2023 | Details |
Microbial Synthetic in vivo Cell Therapy Systems
The MiStiC project aims to develop Clostridium leptum as a stable chassis for localized drug production and delivery, targeting colorectal cancer through engineered biosensors and natural product pathways.
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.
Redesigning aortic endograft: enabling in-situ personalized aneurysm healing
EPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models.
Engineering of bacteria to see light
EOS aims to develop biohybrid living materials by inducing light sensitivity in motile bacteria for remote drug delivery, using a novel "optobacterial-stimulation" method.
Intelligent Device and Computational Software to Control Mechanical Stress and Deformation for Biological Testing
ISBIOMECH aims to develop a novel intelligent system for controlling mechanical environments in biological testing, enhancing in-vitro therapies and drug discovery for various pathologies.